FARMACIA HOSPITALARIA最新文献

{"title":"Intercambio guiado por farmacocinética de factores VIII de vida media estándar a factores VIII de vida media extendida pegilados en la terapia de la hemofilia A en práctica clínica","authors":"Maria Choví-Trull ,&nbsp;Juan Eduardo Megías-Vericat ,&nbsp;Santiago Bonanad Boix ,&nbsp;Saturnino Haya Guaita ,&nbsp;Ana Rosa Cid Haro ,&nbsp;Marta Aguilar Rodriguez ,&nbsp;Jose Luis Poveda Andrés","doi":"10.1016/j.farma.2024.10.005","DOIUrl":"10.1016/j.farma.2024.10.005","url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the differences in pharmacokinetic and clinical parameters (bleeding rates and joint health) before and after switching from standard half-life factor VIII (FVIII) to extended half-life pegylated FVIII in patients with severe/moderate hemophilia A on prophylaxis, one year before and after the switch in real-life.</div></div><div><h3>Method</h3><div>This is a single-center, comparative, observational, sequential, retrospective, and multidisciplinary study. Population pharmacokinetic models from the WAPPS-Hemo® application were used to calculate pharmacokinetic parameters and individualize prophylaxis. The annual rate of total and joint bleeds, joint health (Hemophilia Joint Health Score), plasma half-life and area under the curve ratios, FVIII consumption, administration frequency, and cost were analyzed.</div></div><div><h3>Results</h3><div>Thirty-eight adult patients with hemophilia A who switched from standard half-life FVIII to extended half-life pegylated FVIII were analyzed. Significant improvements (<em>p</em> &lt; 0.05) were observed in all pharmacokinetic parameters, with plasma half-life and area under the curve improvement ratios of 1.5 and 1.9, respectively, as well as reductions in annual total and joint bleeding rates were registered. A higher number of patients with zero total (16.0 vs. 29.0) and joint bleeds (23.0 vs. 33.0) was also observed. The median reductions in administration frequency and dose/kg/week were 30.0% and 19.7%, respectively, avoiding 44.3 infusions/patient/year, resulting in savings of 20,843 €/patient/year. Furthermore, joint health improved (23.0 vs. 21.0; <em>p</em> = 0.017), and target joints resolved after the switch.</div></div><div><h3>Conclusions</h3><div>The pharmacokinetically guided switch from standard half-life FVIII to pegylated FVIII demonstrated significant clinical benefits with reduced bleeding rates and improvements in joint health. Additionally, improvements in pharmacokinetic parameters were observed, allowing for reduced treatment burden by decreasing administration frequency, as well as lower consumption and costs.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages 205-211"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] High-risk medicines: Multidisciplinary program to improve hospital safety","authors":"Maria Dolores Canales-Siguero ,&nbsp;Jose Manuel Caro-Teller ,&nbsp;Siria Pablos-Bravo ,&nbsp;Pedro Pablo Rodríguez-Quesada ,&nbsp;Delicias Quintana-Estelles ,&nbsp;Pilar Gomis-Muñoz ,&nbsp;Angel Tejido-Sanchéz ,&nbsp;Jose Miguel Ferrari-Piquero","doi":"10.1016/j.farma.2025.05.003","DOIUrl":"10.1016/j.farma.2025.05.003","url":null,"abstract":"<div><h3>Introduction</h3><div>High-risk medications (HRMs) are those with a high probability of causing severe or fatal harm when errors occur during their use. Enhancing safety in the management of HRMs is a priority for healthcare authorities. This study presents a multidisciplinary program designed to optimize the safe use of HRMs in adult inpatients at a Level 5 hospital.</div></div><div><h3>Objectives</h3><div>The objectives of the program are: a) To adapt national and international standards on HRM safety to the local setting. b) To define the competencies and responsibilities of the professionals involved. c) To increase the engagement of stakeholders in HRM safety. d) To establish indicators to evaluate the interventions.</div></div><div><h3>Methods</h3><div>The program was developed in three phases: 1) Initial situation analysis: Assessment using the Institute for Safe Medication Practices’ self-assessment questionnaire on medication safety. 2) Protocol development: Creation of a local protocol based on a literature review and multidisciplinary consensus. 3) Action plan implementation: Dissemination, monitoring, and periodic updates of the protocol.</div></div><div><h3>Results</h3><div>The developed protocol included seven general measures, 29 specific measures, and five indicators to evaluate its impact. After the first year of implementation: 71.5% of HRMs were stored in high-security locations within automated dispensing systems, 71.36% of HRM prescriptions were validated within the first 24 hours and a total of 4,366 pharmaceutical interventions were performed.</div><div>Additional measures implemented included: Tall Man Lettering across all information systems, automated alerts for maximum doses in prescribing systems and alerts prompting independent double-checking during HRM dispensing.</div></div><div><h3>Conclusions</h3><div>This program is an effective and transferable model for improving HRM safety in complex hospital settings and fostering a safety culture. Future initiatives should focus on developing a national dashboard with standardized indicators to enable inter-hospital comparisons and identify areas for improvement.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages T225-T229"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis","authors":"Joaquín Borrás-Blasco ,&nbsp;Silvia Cornejo ,&nbsp;Alejandro Valcuende-Rosique ,&nbsp;Rebeca Alcala ,&nbsp;Ana Navalon Bono","doi":"10.1016/j.farma.2024.10.017","DOIUrl":"10.1016/j.farma.2024.10.017","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study was to evaluate the real-world persistence, effectiveness, and safety of secukinumab in adult patients with moderate-to-severe psoriasis in two different hospitals.</div></div><div><h3>Methods</h3><div>Retrospective cohort study that used registries and medical records from 2 different hospitals (February 2015–March 2024). Adults with moderate-to-severe psoriasis who initiated secukinumab treatment were identified and followed-up until March 2024, or disenrollment. Baseline demographic and clinical characteristics studied included sex, age at diagnosis, weight, prior failed treatments, duration of treatment and psoriasis area severity index (PASI) score. Adherence was measured using medication possession ratio (MPR); patients with MPR ≥ 80% were considered adherent. Persistence, effectiveness, safety, and dosage regimen of secukinumab were collected. Kaplan–Meier analysis was used to estimate secukinumab persistence using 1-year intervals.</div></div><div><h3>Results</h3><div>A total of 88 patients with moderate-to-severe psoriasis were included, of whom 45 (51.1%) had not received prior biological treatment. Baseline PASI score was 15.0 ± 2.9 and patients received 1.4 ± 0.8 prior biological treatments. The most common previous biological treatments included anti-TNFα (60.5%) and ustekinumab (20.9%). 34 (38.6%) patients discontinued secukinumab treatment due to the following reasons.</div><div>19 (21.5%) due to a lack of effectiveness, 8 (9.2%), due to achieve only a partial response, and 7 (7.9%) due to adverse effects. Secukinumab persistence was 61.5 ± [21.7] months for all patients. When performing a subgroup analysis, non-naïve patients obtained a persistence of 63.5 ± [12.4] months followed by 54.1 ± [14.8] months for naïve patients (<em>p</em> = .804). Secukinumab persistence at 1 year, 2 years, and 3 years was 72.7%, 51.1%, and 39.8%, respectively.</div></div><div><h3>Conclusions</h3><div>Secukinumab demonstrated persistence in more than 70% of patients with moderate to severe psoriasis after the first year of treatment.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages 200-204"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142773442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estudio prospectivo observacional de seguimiento del tratamiento con psicofármacos iniciados en la unidad de cuidados intensivos","authors":"Laura Doménech-Moral ,&nbsp;Javier Santader-Reboreda ,&nbsp;Meri Martin-Cerezuela ,&nbsp;Amaia Egüés Lugea ,&nbsp;Marcos Buj Vicente ,&nbsp;Sofía Contreras Medina","doi":"10.1016/j.farma.2024.09.007","DOIUrl":"10.1016/j.farma.2024.09.007","url":null,"abstract":"<div><h3>Objective</h3><div>The treatment and prevention of <em>delirium</em> in the intensive care unit (ICU) have gained significant importance in patient care in recent years. Some studies have linked <em>delirium</em> with increased risks of mortality, prolonged hospital stay, and more days of mechanical ventilation. This study aims to analyze the use of psychotropic drugs initiated in the ICU and their continuation upon hospital discharge, as well as to evaluate their contribution to polypharmacy and associated adverse clinical effects.</div></div><div><h3>Method</h3><div>A multicenter prospective observational case study was designed, focusing on patients over 18 years old admitted to the ICU and treated with psychotropic drugs. Data on demographics, variables related to admission and psychotropic drug treatment, as well as clinical outcomes and adverse effects, will be collected. Among other variables, the frequency of psychotropic treatments initiated in the ICU and continued upon discharge from the ICU and the hospital will be measured. Data collection will be performed through review of electronic medical records and prescription programs, and IBM SPSS 20.0 statistical package will be used for analysis.</div></div><div><h3>Discussion</h3><div><em>Delirium</em> is common in ICU patients and is associated with long-term negative consequences. Although antipsychotics are used to treat <em>delirium</em>, their prolonged use can have adverse effects, and their continuation after ICU discharge contributes to polypharmacy. This study aims to provide information on the use of psychotropic drugs initiated in the ICU and their continuation upon discharge, with the goal of identifying opportunities for intervention and reducing unnecessary use of these medications.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages 230-234"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Ethical aspects of AI in hospital pharmacy","authors":"José Manuel Martínez Sesmero","doi":"10.1016/j.farma.2025.06.006","DOIUrl":"10.1016/j.farma.2025.06.006","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages T198-T199"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144592619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recomendaciones para el uso seguro de los medicamentos de alto riesgo en pediatría","authors":"María José Otero ,&nbsp;Belén Rodríguez Marrodan ,&nbsp;Nuria Prieto Santos ,&nbsp;Enrique Villalobos Pinto ,&nbsp;Silvia Manrique Rodríguez ,&nbsp;Rebeca Padilla Peinado ,&nbsp;Cecilia M. Fernández-Llamazares ,&nbsp;Aurora Madrid Rodríguez ,&nbsp;en representación de la Asociación Española de Pediatría, Sociedad Española de Farmacia Hospitalaria y representantes de las comunidades autónomas","doi":"10.1016/j.farma.2025.03.005","DOIUrl":"10.1016/j.farma.2025.03.005","url":null,"abstract":"<div><h3>Objective</h3><div>The objectives of this consensus document were to establish a standardized list of high-risk medications for the pediatric population and to compile the recommended practices for their safe use with the aim of promoting the implementation of medication error prevention programs in health care centers.</div></div><div><h3>Method</h3><div>The Ministry of Health, the Spanish Institute for Safe Medication Practices, the Spanish Association of Pediatrics and the Spanish Society of Hospital Pharmacy and regional administration representatives participated in the project. The <em>Recommendations for the Safe Use of High-Risk Medications</em> was used as reference, and its contents adapted and expanded to address specific issues in the pediatric population based on the current evidence.</div></div><div><h3>Results</h3><div>The document provides a reference list of high-risk medicines in pediatric care. It recommends that health care centers, in addition to prioritizing interventions in relation to anticoagulants, insulins, opioids, neuromuscular blockers, IV potassium, oral methotrexate and cytostatic agents, also consider interventions for IV adrenergic agonists, aminoglycosides and vancomycin, drugs for moderate and minimal sedation, parenteral nutrition and IV paracetamol in pediatric patients. The document emphasizes the need to implement multiple safe practices at every stage of the medication use process, prioritizing those with the greatest effectiveness, and involving pediatricians, pharmacists and other healthcare professionals. It also highlights the importance of active involvement by patients and caregivers. Finally, it provides general guidelines common to all these medications, as well as specific practices for each prioritized pharmacological group or medication, which should be combined to enhance pediatric patient safety.</div></div><div><h3>Conclusion</h3><div>Developing programs to increase the safety of high-risk medications in pediatric patients is essential in order to reduce medication errors in this vulnerable population. The implementation of safe practices should be accompanied by continuous monitoring and periodic updates to guarantee effectiveness and strengthen the safety culture in health care centers.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages 252-260"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144703535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respuesta de los autores a la Carta al Editor sobre el artículo Análisis del retratamiento con anticuerpos monoclonales en la migraña crónica/episódica: datos en vida real","authors":"Patricia García-Lloret","doi":"10.1016/j.farma.2024.10.008","DOIUrl":"10.1016/j.farma.2024.10.008","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages 266-267"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plan Estratégico OrPhar-SEFH 2024–2027","authors":"Mónica Climente Martí ,&nbsp;María Dolores Edo Solsona ,&nbsp;María Reyes Abad Sazatornil ,&nbsp;María Pilar Bachiller Cacho ,&nbsp;Sergio Fernández Espinola ,&nbsp;Paula Guijarro Martínez ,&nbsp;Elena Gras Colomer ,&nbsp;Alicia Herrero Ambrosio ,&nbsp;Silvia Manrique Rodríguez ,&nbsp;Isabel Martín Herranz ,&nbsp;José Manuel Martínez Sesmero ,&nbsp;José Luis Poveda Andrés","doi":"10.1016/j.farma.2025.03.001","DOIUrl":"10.1016/j.farma.2025.03.001","url":null,"abstract":"<div><div>To promote the transformation of hospital pharmacy in the field of rare diseases, the OrPhar-SEFH Strategic Plan 2024–2027 was developed. Twelve hospital pharmacists from the OrPhar-SEFH group participated in the project which was developed in 3 phases: Situation analysis, trends, and current challenges in rare diseases and their impact on the role of hospital pharmacist through literature review, interviews with hospital pharmacists and patients (FundAME and Fedhemo), and SWOT analysis; Definition of lines of action grouped into five strategic axes AEIOU (Alliances, Evidence, Research/Innovation, Optimization, and Union); and Prioritization of lines of action based on impact and feasibility. In order to achieve this, the existing trends and barriers in the field of rare diseases and hospital pharmacy were identified and classified around 4 levers for change: transformation of the care process, patient experience, evaluation and access to orphan drugs, and real-world evidence. The SWOT analysis identified key success factors, and interviews with patients identified their needs in four pillars: role of the hospital pharmacist, patient experience, patient education, and access to treatment. A total of 23 lines of action were agreed upon: Alliances (6), Evidence (3), Research/Innovation (4), Optimization (7), and Union (3). Based on their impact and feasibility, the following were prioritized: promoting hospital pharmacist collaboration in decision-making structures regarding the evaluation and positioning of orphan drugs, enhancing the role of hospital pharmacist in the critical analysis of scientific evidence in rare diseases and its translation to interdisciplinary clinical teams, encouraging the use of Multi-Criteria Decision Analysis methodology in orphan drugs, promoting the integration of hospital pharmacist into interdisciplinary teams managing patients with rare diseases, and creating a network of specialized hospital pharmacist services in rare diseases. Ultimately, the OrPhar-SEFH Strategic Plan 2024–2027 defines the roadmap to enhance the role of hospital pharmacist in addressing rare diseases, improving access and evaluation of orphan drugs, and optimizing the care process to improve health outcomes, quality of life, and patient experience.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages 243-251"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La necesidad de prolongar el uso de antivirales para prevenir recurrencias de la enfermedad ocular por virus de herpes simple. Revisión sistemática","authors":"Laura Ruiz Sifre ,&nbsp;Sylvia Bort Martí ,&nbsp;Vicente Ruiz García ,&nbsp;Ángeles Ruth Bort Martí","doi":"10.1016/j.farma.2025.02.005","DOIUrl":"10.1016/j.farma.2025.02.005","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate in patients with a history of keratitis by herpes simplex virus, ocular recurrences, visual acuity, non-ocular recurrences, stromal keratitis and adverse effects after prolonged treatment with antiviral agents. Registered in Prospero CRD42024556228.</div></div><div><h3>Methods</h3><div>Systematic review of trials identified in CENTRAL, Embase, Medline, <span><span>www.ClinicalTrials.gov</span><svg><path></path></svg></span> and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<span><span>www.who.int/ictrp</span><svg><path></path></svg></span>). Trials of patients with a history of at least one episode of herpes simplex keratitis were included. Participants had to be free of active herpetic disease at the time of enrollment in the trial. Trials had to include oral and/or topical antiviral agents versus placebo or other antivirals, administered for at least 4 weeks. A data extraction was performed by pairs with risk of bias assessment for each trial using Cochrane Risk of Bias; GRADE was used to provide the certainty of evidence for each outcome.</div></div><div><h3>Results</h3><div>Four trials were found that included 1,017 patients. Antivirals in prolonged use protected from recurrences of ocular herpetic disease better than placebo (RR 0.56; 95% CI 0.45–0.70) NNT 6 (4–11); acyclovir was better than placebo in this same action (RR 0.59; 95% CI 0.46–0.74) NNT 8 (5–14), but not different from valacyclovir (RR 1.0; 95% CI 0.37–2.70) NNT not calculated. Prolonged use of antivirals also decreased recurrences of non-ocular herpetic disease (RR 0.56; 95% CI 0.44–0.71) NNT 6 (5–11) and recurrences with stromal keratitis (RR 0.55; 95% CI 0.35–0.85) NNT 17 (10–50). No data were found on visual acuity. Regarding adverse effects, there were no differences between interventions (RR 0.96; 95% CI 0.60–1.54) NNT not calculated. The certainty of evidence was high for ocular and non-ocular recurrences, and low for adverse effects, due to imprecision and inconsistency of the findings.</div></div><div><h3>Conclusions</h3><div>Prolonged use of antivirals protects from ocular, non-ocular recurrences and stromal keratitis safely. The effects on visual acuity are not known.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages 235-242"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Response of the authors to the Letter to the Editor regarding the article Analysis of retreatment with monoclonal antibodies in chronic/episodic migraine: Real-world data","authors":"Patricia García-Lloret","doi":"10.1016/j.farma.2025.01.002","DOIUrl":"10.1016/j.farma.2025.01.002","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages T266-T267"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}